|
Phase I/II Ovarian Cancer Trial - United States
In June 2008, Oncolytics announced that the U.S. National Cancer Institute had started treating patients in a Phase I/II trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers using systemic and intraperitoneal administration of REOLYSIN®. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN®.
See related press releases and documents:
June 10, 2008 - Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN®
January 3, 2008 - Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN®
January 18, 2006 - Oncolytics Biotech Inc. Announces Commencement of Solicitation Process for Clinical Trials Sponsored by the U.S. National Cancer Institute
October 29, 2003 - Oncolytics Biotech Inc. and the U.S. National Cancer Institute to Collaborate on Multiple Clinical Trials with REOLYSIN®
|
